Khoo K H, Douglas E, Azadi P, Inamine J M, Besra G S, Mikusová K, Brennan P J, Chatterjee D
Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523, USA.
J Biol Chem. 1996 Nov 8;271(45):28682-90. doi: 10.1074/jbc.271.45.28682.
The anti-tuberculosis drug, ethambutol (Emb), was previously shown to inhibit the synthesis of arabinans of both the cell wall arabinogalactan (AG) and lipoarabinomannan (LAM) of Mycobacterium tuberculosis and other mycobacteria. However, an Emb-resistant mutant, isolated by consecutive passage of the Mycobacterium smegmatis parent strain in media containing increasing concentrations of Emb, while synthesizing a normal version of AG, produced truncated forms of LAM when maintained on 10 microg/ml Emb (Mikusová, K., Slayden, R. A., Besra, G. S., and Brennan, P. J. (1995) Antimicrob. Agents Chemother. 39, 2482-2489). We have now isolated and characterized the truncated LAMs made by both the resistant mutant and a recombinant strain transfected with a plasmid containing the emb region from Mycobacterium avium which encodes for Emb resistance. By chemical analysis, endoarabinanase digestion, high pH anion exchange chromatography, and mass spectrometry analyses, truncation was demonstrated as primarily a consequence of selective and partial inhibition of the synthesis of the linear arabinan terminal motif, which constitutes a substantial portion of the arabinan termini in LAM but not of AG. However, at higher concentrations, Emb also affected the general biosynthesis of arabinan destined for both AG and LAM, resulting in severely truncated LAM as well as AG with a reduced Ara:Gal ratio. The results suggested that Emb exerts its antimycobacterial effect by inhibiting an array of arabinosyltransferases involved in the biosynthesis of arabinans unique to the mycobacterial cell wall. It was further concluded that the uniquely branched terminal Ara6 motif common to both AG and LAM is an essential structural entity for a functional cell wall and, consequently, that the biosynthetic machinery responsible for its synthesis is the effective target of Emb in its role as a potent anti-tuberculosis drug.
抗结核药物乙胺丁醇(Emb)先前已被证明可抑制结核分枝杆菌和其他分枝杆菌细胞壁阿拉伯半乳聚糖(AG)和脂阿拉伯甘露聚糖(LAM)中阿拉伯聚糖的合成。然而,通过在含有浓度递增的Emb的培养基中连续传代耻垢分枝杆菌亲本菌株分离得到的一株Emb抗性突变体,在合成正常版本的AG的同时,当维持在10微克/毫升Emb的培养基上时会产生截短形式的LAM(米库索娃,K.,斯莱登,R. A.,贝斯拉,G. S.,和布伦南,P. J.(1995年)《抗菌剂与化疗》39卷,2482 - 2489页)。我们现在已经分离并鉴定了由抗性突变体和用含有编码Emb抗性的来自鸟分枝杆菌的emb区域的质粒转染的重组菌株产生的截短LAM。通过化学分析、内切阿拉伯聚糖酶消化、高pH阴离子交换色谱和质谱分析,截短被证明主要是线性阿拉伯聚糖末端基序合成的选择性和部分抑制的结果,该末端基序构成了LAM中阿拉伯聚糖末端的很大一部分,但不构成AG中阿拉伯聚糖末端的很大一部分。然而,在较高浓度下,Emb也影响了用于AG和LAM的阿拉伯聚糖的总体生物合成,导致严重截短的LAM以及阿拉伯糖与半乳糖比例降低的AG。结果表明,Emb通过抑制参与分枝杆菌细胞壁特有的阿拉伯聚糖生物合成的一系列阿拉伯糖基转移酶发挥其抗分枝杆菌作用。进一步得出结论,AG和LAM共有的独特分支末端Ara6基序是功能性细胞壁的必需结构实体,因此,负责其合成的生物合成机制是Emb作为一种强效抗结核药物发挥作用的有效靶点。